Spryte Medical

Executive Summary

Spryte Medical is a privately held medical device company pioneering a neuro Optical Coherence Tomography (nOCT) platform, an AI-enabled intravascular imaging system for the brain's vasculature. Founded in 2019 and headquartered in Irvine, CA, the company aims to transform neurovascular patient care by providing high-resolution, microscopic imaging of arterial walls and devices during procedures such as brain aneurysm treatment. Its technology addresses a critical gap in current imaging modalities, offering real-time, detailed visualization that could improve procedural outcomes and reduce complications. Spryte Medical is advancing its platform through clinical trials and has the potential to establish a new standard of care in cerebrovascular interventions. Despite being in the early stages, Spryte Medical's nOCT platform represents a significant innovation in neurovascular imaging. The company is well-positioned to capture value in a growing market, driven by increasing prevalence of cerebrovascular diseases and demand for minimally invasive procedures. Key risks include regulatory hurdles, competition from established imaging technologies, and the need for clinical validation. However, if successful, Spryte Medical could become a leader in a niche but high-impact segment, making it a compelling opportunity for early-stage investors.

Upcoming Catalysts (preview)

• Q1 2027Completion of First Clinical Data Readout from Brain Aneurysm Study70% success
• Q4 2026FDA 510(k) Clearance or Breakthrough Device Designation50% success
• Q2 2027Series B or C Financing Round60% success